Supernus Pharmaceuticals, Q4 CY2024

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Q4 2024 Supernus Pharmaceuticals Inc Earnings Call
Jack Khattar; President, Chief Executive Officer, Secretary, Director; Supernus Pharmaceuticals Inc Timothy Dec; Chief Financial Officer, Senior Vice President; Supernus Pharmaceuticals Inc Good afternoon,
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. Supernus Pharmaceuticals beat analysts’ revenue expectations by 16.
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Supernus: Q4 Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and stock option expense, were 75 cents per share.
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates
The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, earnings per share came in at $0.27, missing estimates of $0.33.
Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
BioSpace6d
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
pharmaphorum7d
Supernus reports less than super data for depression drug
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...
FierceBiotech7d
Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...